Related Experiment Video
Updated: Jun 25, 2026
08:04
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
Published on: June 10, 2025
Melatonin, as an adjuvant-like agent, enhances platelet responsiveness
Sergio Regodón1, María del Prado Míguez, Isaac Jardín
1Department of Animal Medicine, University of Extremadura, Cáceres, Spain.
Journal of Pineal Research
|February 7, 2009
Summary
Melatonin administration, particularly via slow-release implants, enhanced sheep immune responses to footrot vaccination. This adjuvant effect improved platelet function and calcium signaling, suggesting new vaccine adjuvant strategies.
Area of Science:
- Immunology
- Veterinary Medicine
- Pharmacology
Background:
- Melatonin possesses immunomodulatory properties, suggesting its potential as a vaccine adjuvant.
- Ovine footrot, caused by Dichelobacter nodosus, is a significant economic concern in sheep farming.
- Platelet function plays a role in immune responses and hemostasis.
Purpose of the Study:
- To investigate the effects of melatonin administration (implants vs. injections) on platelet responsiveness in sheep vaccinated against Dichelobacter nodosus.
- To evaluate melatonin's impact on plasma melatonin levels, platelet aggregation, and calcium mobilization post-vaccination.
Main Methods:
- Sheep were administered melatonin via subcutaneous slow-release implants or injections.
- Plasma melatonin levels were measured using radioimmunoassay.
- Platelet aggregation and calcium (Ca2+) mobilization were assessed using aggregometry and spectrofluorimetry, respectively, following vaccination.
Main Results:
- Melatonin administration increased plasma melatonin concentrations, with implants providing a more sustained effect.
- Vaccination and melatonin both enhanced platelet aggregation and reduced thrombin-induced lag-time.
- Melatonin significantly amplified thrombin-evoked Ca2+ release and entry in platelets from vaccinated sheep.
Conclusions:
- Melatonin acts as a beneficial adjuvant, improving platelet function and hemostasis in vaccinated sheep.
- Slow-release melatonin implants offer a promising method for enhancing vaccine efficacy.
- These findings open new avenues for therapeutic manipulation of immune responses through melatonin-based adjuvants.
Related Concept Videos
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...